Long-term extension of the phase 2 GALAXI 1 trial in Crohn's disease: of 151 participants continuing guselkumab, 97.7% with data (85/87) were in clinical remission and 51.7% in endoscopic remission at week 240; by nonresponder imputation, 46.0% of all randomised.
RCTn = 185
Afzali et al. Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial